The DOI matches its Crossref record.
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
Open accessAbstract
OBJECTIVES: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. DESIGN: Randomized single-blinded clinical trial. SETTING: Apac, Uganda, an area of very high malaria transmission intensity. PARTICIPANTS: Children aged 6 mo to 10 y with uncomplicated falciparum malaria. INTERVENTION: Treatment of malaria with AL or DP, each following standard 3-d dosing regimens. OUTCOME MEASURES: Risks of recurrent parasitemia at 28 and 42 d, unadjusted and adjusted by genotyping to distinguish recrudescences and new infections. RESULTS: Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%-26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%-19%) of follow-up. Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%-12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%-16%). Patients treated with DP had a lower risk of recurrent parasitemia due to non-falciparum species, development of gametocytemia, and higher mean increase in hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs. CONCLUSION: DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery. DP thus appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. To maximize the benefit of artemisinin-based combination therapy in Africa, treatment should be integrated with aggressive strategies to reduce malaria transmission intensity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Artemisinin-based combination therapy for treating uncomplicated malaria
Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007483.pub2 · Cited by 286
Antimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
Self-citationDrug-Resistant Malaria: The Era of ACT
Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0099-y · Cited by 121
Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050227 · Cited by 15
Metadata
- Authors
- Kamya, M. R., Yeka, A., Bukirwa, H., Lugemwa, M., Rwakimari, J. B., Staedke, S. G., Talisuna, A. O., Greenhouse, B., Nosten, F., Rosenthal, P. J., Wabwire-Mangen, F., & Dorsey, G.
- Venue
- PLoS Clinical Trials
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-05-18
- Volume
- 2
- Issue
- 5
- Pages
- e20
- ISSN
- 1555-5887 (ISSN-L)
- OpenAlex
- W2115398829
- Cited by
- 169
- References
- 0
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial. https://app.cochat.ai/papers/10.1371/journal.pctr.0020020
- The paper
- Kamya, M. R., Yeka, A., Bukirwa, H., Lugemwa, M., Rwakimari, J. B., Staedke, S. G., Talisuna, A. O., Greenhouse, B., Nosten, F., Rosenthal, P. J., Wabwire-Mangen, F., & Dorsey, G. (2007). Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial. PLoS Clinical Trials. https://doi.org/10.1371/journal.pctr.0020020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.